Category Archives: Psoriasis

Psoriasis Revolution Review - Does Psoriasis Revolution Works
Psoriasis Revolution Review http://tinyurl.com/RevolutionPsoriasisCure This is an uncommon suggestion get rid of psoriasis forever created by an expert and also a previous experience Dan...

By: Digital Reviews

Read the rest here:
Psoriasis Revolution Review - Does Psoriasis Revolution Works - Video

World Psoriasis Day - Swimming for Psoriasis - 28.10.2014
On October 28th, EADV invited the press, VIPs, politicians, dermatologists and patients associations to swim for psoriasis in the frame of the World Psoriasis Day. Psoriasis is not contagious,...

By: European Academy of Dermatology and Venereology

Here is the original post:
World Psoriasis Day - Swimming for Psoriasis - 28.10.2014 - Video

Psoriasis Revolution By Dan Crawford | Amazing Psoriasis Revolution By Dan Crawford
http://www.tinyurl.com/psoriasisrevolutionnow Psoriasis Revolution By Dan Crawford: Lots of people around the globe suffer from a horrible skin disease known as psoriasis, a chronic dermatological...

By: Ross Castle

Original post:
Psoriasis Revolution By Dan Crawford | Amazing Psoriasis Revolution By Dan Crawford - Video

Psoriasis and other skin diseases Ayurrekha |Ithalukal 12th Nov 2014
Guest Dr. K. Pavithran.

By: asianetnews

Read this article:
Psoriasis and other skin diseases Ayurrekha |Ithalukal 12th Nov 2014 - Video

How to get rid of super dry skin psoriasis, eczema and more!
This video will explain how to get rid of dry skin, psoriasis and skin disorder naturally. Watch now and comment below!

By: Nava Natural

Original post:
How to get rid of super dry skin psoriasis, eczema and more! - Video

PHILADELPHIA Those experiencing psoriasis, psoriatic arthritis, and rheumatoid arthritis are at higher risk for major adverse cardiovascular events (MACE) and cardiovascular death, according to a multi-institutional study led by Penn Medicine researchers published online last month in Annals of the Rheumatic Diseases.

The researchers used primary care records from The Health Improvement Network (UK) between from 1994 to 2010 of adults 18 to 89 years old, including 8,700 with psoriatic arthritis (PsA), 138,000 with psoriasis, nearly 42,000 experiencing rheumatoid arthritis (RA), and 82,000 controls experiencing none of the conditions.

Slightly more than half the studys psoriatic arthritis and rheumatoid arthritis patients were prescribed a disease-modifying antirheumatic drug. At least 65 percent of patients with PsA and RA were prescribed non-steroidal anti-inflammatory drugs compared with 24 percent of those with psoriasis and 47 percent of controls.

The researchers looked at the rate of MACE in psoriatic arthritis patients, psoriasis, and rheumatoid arthritis after adjusting for CV risk factors. Psoriatic arthritis patients were 36 percent more likely than the control group to experience a heart attack, whether or not they were prescribed a DMARD.

Psoriasis, a chronic immune disease, affects 7.5 million people in the U.S., according to the National Psoriasis Foundation. The Centers for Disease Control and Prevention report that 10 to 20 percent of those with psoriasis develop psoriatic arthritis. Rheumatoid arthritis afflicts more than 1 million U.S. adults, the American College of Rheumatology reports.

We expected the increased risk of heart disease in these patients, said Alexis Ogdie, MD, MSCE, assistant professor of rheumatology and lead author of the study. Previous studies link whole-body inflammation with premature plaque buildup in the arteries.

Senior author Joel M. Gelfand, MD MSCE noted that a surprising finding was that the increased risk of MACE and CV mortality in patients with more severe psoriasis was similar in magnitude to patients with rheumatoid arthritis.

This finding, Gelfand said, emphasizes the clinical significance of cardiovascular risk associated with more severe psoriasis.

Earlier studies linked psoriasis and rheumatoid arthritis to heart disease, but little was known about a link between psoriatic arthritis cases and heart disease. Gelfand and Ogdie are currently conducting clinical trials to determine if treatments used for psoriasis, psoriatic arthritis, and rheumatoid arthritis improve aortic vascular inflammation associated with these conditions (http://clinicaltrials.gov/show/NCT01553058).

Other Penn co-authors of thestudy include Kevin Haynes, Samantha Maliha, Yihui Jiang, Steven Kimmel, Sean Hennessy, David J Margolis, and Joel M. Gelfand.

Link:
Penn Medicine Study Finds Increased Risk of Cardiac Events in Those with Psoriatic Arthritis, Psoriasis, and ...

Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. Pipelines are of prime importance as far as pharma/biotech companies are concerned. These companies spend a significant amount in advancing their pipelines.

AstraZeneca ( AZN ) and partner Amgen ( AMGN ) announced encouraging results from the pivotal, multi-arm phase III AMAGINE-3 study (n>1800) on their psoriasis candidate, brodalumab.

The study evaluated the safety and efficacy of brodalumab (140 mg and 210 mg) doses given every two weeks to patients suffering from moderate-to-severe plaque psoriasis in comparison to placebo and Johnson & Johnson's ( JNJ ) Stelara. Amgen and AstraZeneca said that the primary as well as secondary endpoints were achieved.

Results showed that a greater proportion of patients treated with brodalumab 210 mg (36.7%) and brodalumab 140 mg (27%) achieved total clearance of skin disease as measured by the Psoriasis Area Severity Index (PASI 100) compared to Stelara (18.5%) and placebo (0.3%).

As far as PASI 75 score (at least a 75% improvement in disease severity) is concerned, results showed that a higher number of patients on brodalumab 210 mg (85.1%) achieved the same as compared to those on brodalumab 140 mg (69.2%), Stelara (69.3%) and placebo (6%).

We note that the companies' AMAGINE program consists of three phase III studies - AMAGINE-1, AMAGINE-2 and AMAGINE-3. While results from the AMAGINE-2 study are expected by year end, AstraZeneca and Amgen have already revealed encouraging results from the AMAGINE-1 study (read more: Amgen-AstraZeneca Psoriasis Drug Scores ).

We are encouraged by the positive results so far from the AMAGINE program on brodalumab. However, the psoriasis market looks extremely crowded given the presence of products like Stelara, Enbrel and Otezla. The successful development of brodalumab, an important candidate for both AstraZeneca and Amgen, is crucial. Brodalumab is also being developed for the treatment of asthma. According to AstraZeneca, analyst estimates for brodalumab range between $0.5 billion to $1.5 billion.

Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. A better-ranked stock in the health care sector is AMAG Pharmaceuticals, Inc. ( AMAG ) carrying a Zacks Rank #1 (Strong Buy).

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

More:
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog

I had Psoriasis for years and dry body brushing fixed it!
With any dry skin condition you need a Holistic approach to healing, include Dry Brushing, eating healthy, relaxation exercises and regular exercise. "I had ...

By: Bodecare Jodie Smith

Continue reading here:
I had Psoriasis for years and dry body brushing fixed it! - Video

Testimonios dermaoil Psoriasis y Dermatitis
Testimonios de personas aliviadas utilizando productos dermaoil 100%naturales http://www.soussorganic.com lada sin costo 01800 0990502.

By: cynthia trevino

Follow this link:
Testimonios dermaoil Psoriasis y Dermatitis - Video

Dr Ang Yong Guan - Emotional Resilience Workshop
Organised by Leo Pharma and supported by the Psoriasis Association of Singapore, Psoriasis patients and friends were invited for this insightful talk by Dr A...

By: The Psoriasis Man Ray Chua

Go here to see the original:
Dr Ang Yong Guan - Emotional Resilience Workshop - Video